TIDMAVO
Advanced Oncotherapy PLC
27 April 2022
Reach non-regulatory announcement
27 April 2022
ADVANCED ONCOTHERAPY PLC
("Advanced Oncotherapy" or the "Company")
Launch of a video showcasing progress on LIGHT system
process
Advanced Oncotherapy (AIM:AVO), the developer of LIGHT, the
next-generation proton therapy system for cancer treatment, today
announces the launch of a video showcasing progress on the LIGHT
system infrastructure and set-up at its assembly and integration
site located in Daresbury, Cheshire.
As outlined in the operational update released by the Company on
26 April 2022, it has made good progress along its timescale of
summer 2022 for having a fully operational LIGHT system operating
at 230 MeV.
-- Finalised building rooms for the infrastructure required to
accommodate the LIGHT machine and its ancillary equipment, which
have more than 34,000 components.
-- The LIGHT machine assembly is on track. To date, 20 of the 21
accelerating modules needed to accelerate protons to an energy of
230 MeV have been radio-frequency (RF) conditioned and the control
systems are in place.
-- Patient treatment will take place in the treatment room which
is located at the end of the accelerator where a state-of-the-art
robot chair, with CT scanner and X-Ray panels for accurate patient
positioning, has been installed.
The video launched today , and which is available on the
Company's website , showcases the various complex elements at play
in the integration of the Company's LIGHT system:
Further details on the specificities of the machine, its control
systems and the patient treatment facility, which are highlighted
in the video, are detailed below:
-- The accelerator, currently under assembly, is powered by:
o 13 klystrons, which provide high radio-frequency power to the
machine to accelerate the proton beam, operating at 3 GHz, inducing
an electromagnetic field inside the LIGHT accelerating modules that
is oscillating at a frequency of three billion times per
second.
o Four inductive output tubes (IOTs), operating at 750 MHz which
generate the relevant power for the radiofrequency quadrupole
(RFQ).
-- The accelerator is cooled, kept under vacuum and monitored by
beam diagnostics and the Company's time-of-flight energy
measurement algorithm.
-- The proprietary LIGHT Accelerator Control System integrates
more than 300 different devices and is driven by operators in the
control room:
o The Company and its partners have developed c.250 front end
control software instances to accelerate, steer and monitor the
proton beam.
o The measuring systems calculate the speed of protons in
picosecond, the time it takes light to travel one third of a
millimetre.
o 20 Gb of nominal data is transferred per day to support the
beam optimisation and control.
-- Protons go through a gallery of accelerators moving as a 200
Hz pulsed beam through the RFQ, the SCDTLs and then through the 15
CCLs accelerating up to a maximum of 230 MeV.
o These accelerating structures have been aligned and
pre-aligned, requiring fine adjustment devices to position
components such as the Permanent Magnet Quadrupoles, which are used
to focus the proton beam, to a position accuracy of 50 <MU>m,
the average diameter of human hair being 75 <MU>m.
-- LIGHT is the first proton therapy system integrated with a
dedicated vertical CT scanner. The diagnostic CT scanner, which
weighs over 2,000 kg and can be moved with sub-millimetre accuracy,
has been mounted vertically to aid patient comfort during
treatment.
- ENDS -
Advanced Oncotherapy plc www.avoplc.com
Dr. Michael Sinclair, Executive Chairman Tel: +44 (0) 20 3617 8728
Nicolas Serandour, CEO
Allenby Capital Limited (Nomad and
Joint Broker)
Nick Athanas / Liz Kirchner (Corporate Tel: +44 (0) 20 3328 5656
Finance)
Amrit Nahal / Matt Butlin (Sales
and Corporate Broking)
SI Capital Ltd (Joint Broker)
Nick Emerson Tel: +44 (0) 1483 413 500
Jon Levinson Tel: +44 (0) 20 3871 4066
FTI Consulting (Financial PR & IR) advancedoncotherapy@fticonsulting.com
Simon Conway / Rob Winder Tel: +44 (0) 20 3727 1000
Notes
-- Inductive output tubes (IOT) - IOTs are high power
radio-frequency generators used to bring the relevant power to the
RFQ.
-- Radio-frequency quadrupole (RFQ) - The RFQ is a copper
accelerating structure which focuses, bunches and accelerates
protons up to 5MeV. The RFQ sits between the proton source and the
side-coupled drift tube linacs.
-- Side-coupled drift tube linacs (SCDTLs) - The LIGHT
accelerator includes four SCDTL modules which accelerate protons
from 5MeV to 37.5MeV. The SCDTLs sit between the RFQ and the
CCLs.
-- Coupled cavity linacs (CCLs) - The CCL structures or "higher
speed accelerators" are an essential part of the LIGHT Accelerator.
They consist of a series of "cells" which accelerate the protons
from 37.5MeV to energies that can be applied usefully to a clinical
setting (70MeV to 230MeV).
-- Klystrons - The Klystrons provide high radio-frequency power
to the machine to accelerate the proton beam.
-- Permanent magnet quadrupoles (PMQs) - The PMQs are used to
focus and align the proton beam. They are placed along the LIGHT
accelerator within the SCDTLs and CCLs (in between acceleration
tanks) and also in the medium energy beam transfer line.
-- RF conditioning - The radio-frequency (RF) conditioning
involves gradually increasing the input power until there is an
electrical "breakdown". After each breakdown, the accelerating
modules can sustain an increase in the input power. This process is
continued and iterative until the power reached is 20% above the
nominal values. This ensures great stability when operating at
nominal power. As the Daresbury LIGHT system is expected to be the
first linear proton accelerator to be commissioned for medical use,
the RF conditioning is unprecedented, hence carrying some level of
uncertainty with regards to the time needed to complete this
important task. This risk has been significantly removed following
recent progress.
About Advanced Oncotherapy Plc
Advanced Oncotherapy, a UK headquartered company with offices in
London, Geneva, The Netherlands and in the USA, is a provider of
particle therapy with protons that harnesses the best in modern
technology. Advanced Oncotherapy's team "ADAM," based in Geneva,
focuses on the development of a proprietary proton accelerator
called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's
compact configuration delivers proton beams in a way that
facilitates greater precision and electronic control.
Advanced Oncotherapy will offer healthcare providers affordable
systems that will enable them to treat cancer with innovative
technology as well as expected lower treatment-related side
effects.
Advanced Oncotherapy continually monitors the market for any
emerging improvements in delivering proton therapy and actively
seeks working relationships with providers of these innovative
technologies. Through these relationships, the Company will remain
the prime provider of an innovative and cost-effective system for
particle therapy with protons.
About Reach announcements
This is a Reach announcement. Reach is an investor communication
service aimed at assisting listed and unlisted (including AIM
quoted) companies to distribute media only / non-regulatory news
releases into the public domain. Information required to be
notified under the AIM Rules for Companies, Market Abuse Regulation
or other regulation would be disseminated as an RNS regulatory
announcement and not on Reach.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAPPUBPCUPPPGQ
(END) Dow Jones Newswires
April 27, 2022 02:02 ET (06:02 GMT)
Advanced Oncotherapy (LSE:AVO)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Advanced Oncotherapy (LSE:AVO)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024
